PRTA vs. GYRE, BLTE, IRWD, SYRE, PCRX, LGND, GMTX, MIRM, COLL, and MNKD
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Gyre Therapeutics (GYRE), Belite Bio (BLTE), Ironwood Pharmaceuticals (IRWD), Spyre Therapeutics (SYRE), Pacira BioSciences (PCRX), Ligand Pharmaceuticals (LGND), Gemini Therapeutics (GMTX), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Gyre Therapeutics (NASDAQ:GYRE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 2.9% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Gyre Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -193.17%. Prothena's return on equity of 0.00% beat Gyre Therapeutics' return on equity.
In the previous week, Prothena had 12 more articles in the media than Gyre Therapeutics. MarketBeat recorded 20 mentions for Prothena and 8 mentions for Gyre Therapeutics. Prothena's average media sentiment score of 0.50 beat Gyre Therapeutics' score of -0.30 indicating that Gyre Therapeutics is being referred to more favorably in the media.
Gyre Therapeutics has higher revenue and earnings than Prothena.
Gyre Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Prothena received 600 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
Prothena has a consensus price target of $67.00, suggesting a potential upside of 213.96%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Prothena is more favorable than Gyre Therapeutics.
Summary
Prothena beats Gyre Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
